Savara (STU:YB4P) Other Long-Term Liabilities : €0.19 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Savara Other Long-Term Liabilities?

Savara's other long-term liabilities for the quarter that ended in Mar. 2024 was €0.19 Mil.

Savara's quarterly other long-term liabilities declined from Sep. 2023 (€0.27 Mil) to Dec. 2023 (€0.23 Mil) and declined from Dec. 2023 (€0.23 Mil) to Mar. 2024 (€0.19 Mil).

Savara's annual other long-term liabilities declined from Dec. 2021 (€0.10 Mil) to Dec. 2022 (€0.05 Mil) but then increased from Dec. 2022 (€0.05 Mil) to Dec. 2023 (€0.23 Mil).

Savara Other Long-Term Liabilities Historical Data

The historical data trend for Savara's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Other Long-Term Liabilities Chart

Savara Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Savara Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Savara Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Savara Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Savara's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Savara (STU:YB4P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (STU:YB4P) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

SVRA:USA

Address

6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746

Website

https://www.savarapharma.com

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Savara (STU:YB4P) Headlines

No Headlines